Tute Genomics and Patients Know Best Partner to Bring ‘Precision Medicine' a Step Closer

Share Article

Patient-controlled medical record, combined with Tute Genomics' interpretation platform, enables genome-guided medicine.

Tute Genomics is today teaming up with UK-based Patients Know Best – the world’s first fully patient controlled medical records system – to make ‘precision medicine’ a reality to patients across the globe.

Operating a cloud-based software platform, Tute Genomics specializes in genome analysis, creating meaningful reports of an individual’s full genomic profile that doctors and patients alike can interpret and use to gain meaningful and actionable insights about their health.

The partnership between the two companies will mean that for the first time a patient’s full genetic profile – and one that is easy to work with and understand – can be stored within their healthcare record. For the patient, this will ultimately result in receiving healthcare services that are precision-made for their particular condition – based on their individual genome sequence.

Dr Reid Robison, CEO of Tute Genomics said,“We’re enthusiastic about this new partnership with Patients Know Best because we share the same philosophies about pushing genomic medicine forward. Patients Know Best believes in creating a system that will reduce errors and raise quality of healthcare and that is the purpose of the Tute genomics platform; enabling precision medicine. Tute Genomics is working hard to make genomics more accessible to healthcare, research and even consumers, in order to advance individualized, genome-guided medicine.”

Over the past few years genomic sequencing – 'mapping out' a person’s full DNA – has become far cheaper and therefore far more feasible. Full genome sequencing involves testing 25,000 separate genomes and 'reading off' 6 billion letters (3 billion ‘base pairs) in any given human genome. Approximately 10 years ago it cost over $100 million to sequence a person’s full genome. Today, the cost stands at around $1000.

Dr Mohammad Al-Ubaydli, CEO of Patients Know Best said, “When doctors know an individual’s genomic profile they can design plans that exactly treat their condition. For example, gene tests can predict whether or not a patient with breast cancer will benefit from a certain type of chemotherapy, or a patient with an infection can safely receive powerful antibiotics. We believe that before long, everyone will get his or her genome sequenced. Tute is providing the most powerful genetic analysis in the hands of patients.”

About Patients Know Best
Patients Know Best is the world’s first patient-controlled medical records system. It is a fully secure online tool which enables patients to better organise, manage and control their own health care provision – it also saves the time of physicians through allowing secure, online consultations. Founded by Dr. Mohammad Al-Ubaydli, a physician, programmer and expert in IT in healthcare, Patients Know Best has won social enterprise awards for its focus on patient care. Patients Know Best’s first customers include Great Ormond Street Hospital, St Marks Hospital and NHS South Devon. Patients Know Best integrates fully into the NHS secure network and is available for use by any patient with any clinician anywhere in the world. It is now used by over 30 hospitals in the UK, USA, Holland, Ireland, Kuwait, Australia and Hong Kong. Patients Know Best complies fully with UK NHS information governance requirements as well as the EU data protection act and US HIPAA legislation for dealing with medical data. http://www.patientsknowbest.com

About Tute Genomics
Tute Genomics is a USA-based company developing innovative cloud-based solutions to accelerate genetic discovery and enable precision medicine. Tute created a clinical genome interpretation platform that assists researchers in identifying disease genes and biomarkers, and assists clinicians/labs in performing genetic diagnosis. Given sequencing data on a genome or a panel of genes, Tute can return over 125 annotations on variants and genes, perform family-based, case/control or tumor sample analyses to identify causal disease genes, and generate clinical reports for clinicians to focus on clinically relevant and actionable findings. Tute is built on the expertise that developed ANNOVAR, the most widely used genome annotation & interpretation technology with over 800 scientific publications. The genome revolution is here, and Tute envisions a future where clinical reports on genomes are interactive and integrated into medical records, and aims to be the 'dropbox for genomes' for clinicians and patients alike. To learn more please visit http://www.tutegenomics.com.

Chris Smith, Swarm Communications
+44 (0) 7989 321 743

Dr Mohammad Al-Ubaydli, Patients Know Best
Patients Know Best
+44 7724 189 415

Dr Reid Robison
Tute Genomics
+1 858 779 4363

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Mary Brown
Tute Genomics
+1 (858) 779-4363
Email >
Visit website